Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 23, 2018. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a specific equity transaction involving American Depositary Shares (ADSs).
| Metric | Value |
|---|---|
| Instrument | American Depositary Shares (ADSs) |
| Transaction Type | Vesting of Share Value Plan award |
| Total Volume | 2,163 ADSs |
| Withheld for Tax | 1,066 ADSs |
| Transaction Price | $38.346 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the vesting of an award for Mr. B McNamara, CEO of Consumer Healthcare, on January 22, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of an insider transaction.
Key Facts for Investor Verification
- The transaction involved the vesting of 2,163 ADSs for Mr. B McNamara.
- Approximately 49% of the vested shares (1,066 ADSs) were withheld to satisfy tax liabilities.
- The transaction price was $38.346 per ADS.
- The filing is an initial notification of the transaction, not an amendment.